Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year : vimarsana.com

22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 MPOSITIVE MOMENTUM AND OUTLOOK FOR 2023DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDUSTRYHAMBURG

Related Keywords

Hamburg , Germany , France , Evotec Biologics , Hinnerk Rohwedder , Bristol Myers Squibb , Eli Lilly , Evotec Modena , Werner Lanthaler , Europe Toulouse , Evotec Seview , Gabriele Hansen , Volker Braun , Department Of Defense , European Investment Bank , Sernova Corp , Us Department Of Defense , Antibodies Program , Global Corporate Communications , Evotec Se Frankfurt Stock Exchange , Boehringer Ingelheim , Evotec Group , Head Of Global Corporate Communications , Nasdaq , Linkedin , Frankfurt Stock Exchange , Campus Curie , Investment Bank , Chief Financial Officer , Accelerated Antibodies , Chief Executive Officer , Global Investor Relations , Evotec , Reliminary , Iscal , Ear , 022 , Esults , Head , Urve , Ery , Strong , Erformance , Hallenging ,